반응식
CC1(C)C(C)(C)OB([C:9]2[CH:14]=[CH:13][C:12]([N+:15]([O-:17])=[O:16])=[CH:11][CH:10]=2)O1.Br[C:20]1[CH:21]=[CH:22][C:23]([O:26][CH3:27])=[N:24][CH:25]=1>C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1>[CH3:27][O:26][C:23]1[CH:22]=[CH:21][C:20]([C:9]2[CH:10]=[CH:11][C:12]([N+:15]([O-:17])=[O:16])=[CH:13][CH:14]=2)=[CH:25][N:24]=1참가 물질
4
실험 절차
The title compound was prepared from 4,4,5,5-tetramethyl-2-(4-nitro-phenyl)-[1,3,2]dioxaborolane (899 mg, 3.60 mmol), 5-bromo-2-methoxy-pyridine (616 mg, 3.28 mmol) and Pd(PPh3)4 (380 mg, 0.360 mmol) according to the procedure in Example 44, step (b) (615 mg, 94%). Mass spectrum (ESI, m/z): Calcd. for C12H10N2O3, 231.0 (M+H), found 231.2.
출처 및 근거
- ORD 기록
- ord-c434bf5561f044a8be82bf7ef06044b9
- 출처 데이터셋
- uspto-grants-2010_09
- 특허 번호
- US07790724B2
연결된 노트
불러오는 중…